We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Topiramate-Induced Intractable Cough During Migraine Prophylaxis.
- Authors
Maggioni, Ferdinando; Mampreso, Edoardo; Mainardi, Federico; Lisotto, Carlo; Malvindi, Maria Lucia; Zanchin, Giorgio
- Abstract
( Headache 2010;50:301-304) Topiramate is a highly effective drug in migraine prophylaxis and is considered a first-line treatment. The evidence for the efficacy of topiramate is based upon the results of several large, randomized, double-blind, placebo-controlled trials. Adverse events (AEs) are common and require discontinuation of the treatment in about 20-25% of patients, but they are rarely severe. There are reviews regarding topiramate-related AEs representing a large number of patients treated in controlled trials. The most common AEs are weight loss, dizziness, somnolence, abnormal thinking, fatigue, ataxia, confusion, paresthesias, impaired concentration, nervousness, amnesia, and language difficulties. The development of cough has never been reported as an AE during topiramate prophylaxis for migraine. We present 3 cases in which the prophylactic treatment for migraine with topiramate was discontinued due to the onset of primary intractable coughing.
- Subjects
COUGH; TOPIRAMATE; MIGRAINE; ANTICONVULSANTS; REFLEXES
- Publication
Headache: The Journal of Head & Face Pain, 2010, Vol 50, Issue 2, p301
- ISSN
0017-8748
- Publication type
Article
- DOI
10.1111/j.1526-4610.2009.01515.x